title: [Antibacterial activities of piperacillin in several fresh clinical isolates].
abstract: We investigated activity of piperacillin (PIPC) in comparison with 8 antibacterial reference drugs against several fresh clinical strains isolated from patients with infectious diseases in the respiratory tract and after surgical interventions in 1999. The following results were obtained: 1. PIPC had its MIC90 of 0.12-6 micrograms/ml in Gram-positive bacteria (Methicillin susceptible Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pneumoniae, Enterococcus faecalis) and showed its MIC of 1 microgram/ml or higher in 9 possible PRSP strains out of 38 isolates of S. pneumoniae but there were no possible isolates with evident resistance in other species of bacteria. 2. PIPC showed favorable antibacterial activities as its MIC90 were 2-8 micrograms/ml in Gram-negative bacteria (Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Citrobacter freundii, Pseudomonas aeruginosa, Moraxella (Branhamella) catarrhalis, Haemophilus influenzae), except for P. mirabilis in which its MIC90 was as high as 64 micrograms/ml. 11 out of 39 isolates of P. mirabilis were resistant to other drugs such as PIPC, ABPC, CTM and CZOP. 3. PIPC had its MIC90 of > 128 micrograms/ml in Bacteroides fragilis. From these results, PIPC was considered highly effective in several infections in view of maintaining its favorable antibacterial activities in several causative bacteria even today when 20 years had passed since its first application to clinical practice.
authors.affiliation: Chemotherapy Division, Mitsubishi-Kagaku Bio-Clinical Laboratories, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Matsuzaki
authors.forename: H
authors.initials: H
authors.lastname: Koyama
authors.forename: K
authors.initials: K
authors.lastname: Omika
authors.forename: M
authors.initials: M
authors.lastname: Hasegawa
authors.forename: Y
authors.initials: Y
authors.lastname: Sato
authors.forename: I
authors.initials: I
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Kaku
mesh_terms: D001441:Bacteroides fragilis / Q000187:drug effects; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology*; D010878:Piperacillin / Q000494:pharmacology*; D011183:Postoperative Complications / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000382:microbiology; D013530:Surgical Wound Infection / Q000382:microbiology
chemical_list: D010406:Penicillins; D010878:Piperacillin